Results 121 to 130 of about 16,120 (219)

Chest pain in a patient with transthyretin cardiac amyloidosis: A case report

Clinical Case Reports
Key Clinical Message Patients with transthyretin cardiac amyloidosis (ATTR‐CM) commonly present with dyspnea, fatigue, and edema. In our case, the main presentation was exertional angina, which was atypical in patients with ATTR‐CM and should be paid ...
Linfeng Xie, Suxin Luo, Bi Huang
doaj   +1 more source

A Rare Culprit or an Elusive Culprit in Disguise? Unraveling Wild-Type ATTR Cardiac Amyloidosis in Heart Failure With Reduced Ejection Fraction

Journal of Investigative Medicine High Impact Case Reports
Cardiac amyloidosis (CA) is a rare disorder caused by the deposition of abnormal proteins called amyloid in the myocardium, leading to dysfunction. The 2 most common forms of amyloidosis are AL (light chain) and ATTR (transthyretin).
Jose Loayza Pintado MD, Taiwo Ajani MD, Daniela Hernandez MD, Everardo Cobos MD   +3 more
doaj   +1 more source

Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France

International audienceEarly access experience in France with tafamidis meglumine, a selective transthyretin stabilizer for transthyretin-related amyloidosis cardiomyopathy (ATTR-CM), following transthyretin-related amyloidosis (ATTR) polyneuropathy ...
Legallois, Damien, Lequeux, Benoit, Fievez, Stephane, Quinault, Aurore, Hippocrate, Aurelie, Eicher, Jean-Christophe, Josse, Constant, Damy, Thibaud, Réant, Patricia, Rudant, Jeremie, Bauer, Fabrice, Noirot Cosson, Charlotte, Lairez, Olivier, Dubois, Margaux, Habib, Gilbert, Squara, Pierre-Alexandre, Inamo, Jocelyn, Jeanneteau, Julien, Bartoli, Mathilde, Kharoubi, Mounira   +19 more
core   +1 more source

Popeye’s sign and transthyretin amyloidosis

European Heart Journal, 2022
Nobuhiro Tahara, Akihiro Honda, Mitsuharu Ueda, Yoshihiro Fukumoto   +3 more
openaire   +2 more sources

Gut-Heart Axis: Microbiome Involvement in Wild-Type Transthyretin Amyloidosis. [PDF]

Int J Mol Sci
López-Tenorio II, Constantino-Jonapa LA, Jaimez-Alvarado S, Hernández-Quiroz F, Jorge-Galarza E, Escalona-Montaño AR, Amedei A, Soria-García R, Berrios-Barcenas EA, Aguirre-García MM.   +9 more
europepmc   +1 more source

Polyneuropathy in Wild-Type Transthyretin Amyloidosis. [PDF]

Eur J Neurol
Sciarrone MA, Vitali F, Guglielmino V, Romano A, Siconolfi G, Ceccanti M, Inghilleri M, Chimenti C, Graziani F, Lillo R, Libonati L, Cambieri C, Moret F, Stifano V, Luigetti M.   +14 more
europepmc   +1 more source

Evaluation of serum neurofilament light chain, GFAP, and peripherin as biomarkers in hereditary transthyretin amyloidosis. [PDF]

Sci Rep
Anan I, Johannson G, Pilebro B, Wixner J, Heldestad V, Arvidsson S, Olsson M.   +6 more
europepmc   +1 more source

Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review. [PDF]

JACC CardioOncol
Vaishnav J, Bampatsias D, Boursiquot BC, Brailovsky Y, Hsu K, Zigterman J, Chakraborty R, Wechalekar A, Pavia PG, Witteles R, Hanna M, Karam C, Maurer MS, Griffin JM.   +13 more
europepmc   +1 more source

The patient's voice: real-world experiences of a transthyretin amyloidosis focus group. [PDF]

BMC Health Serv Res
López MA, Ripoll-Vera T, Sevilla T, Salamanca-Bautista P, Mediavilla I, Soto JF, CARABELA-ATTR Scientific Committee.   +6 more
europepmc   +1 more source

Autonomic dysfunction in patients with wild-type transthyretin amyloidosis. [PDF]

J Neurol
Kleinveld VEA, Wanschitz J, Hotter A, Horlings CGC, Leys F, Ungericht M, Pölzl G, Granata R, Fanciulli A, Löscher WN.   +9 more
europepmc   +1 more source